This study explores a new treatment for relapsed (came back) or refractory (doesn't respond) Multiple Myeloma (a type of blood cancer). The treatment involves a drug called CC-92480 (BMS-986348), combined with other medicines to see if it's safe and effective. Participants should have tried other treatments before joining this study. If you join, you'll be monitored for safety and how well the drug works.

• The study involves multiple visits, as it checks safety and drug levels over time.
• Participants must have a type of myeloma that hasn't responded to other treatments.
• Risks include potential side effects from the drug or interactions with previous treatments.

To join, you should not have certain other health issues or recent infections. You must also agree to a pregnancy prevention plan. This study can help advance treatment for Multiple Myeloma, but it does require a commitment to follow the study rules and attend all necessary appointments.